PMID- 36458011
OWN - NLM
STAT- MEDLINE
DCOM- 20221205
LR  - 20221205
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 13
DP  - 2022
TI  - The effects of dendritic cell-based vaccines in the tumor microenvironment: 
      Impact on myeloid-derived suppressor cells.
PG  - 1050484
LID - 10.3389/fimmu.2022.1050484 [doi]
LID - 1050484
AB  - Dendritic cells (DCs) are a heterogenous population of professional antigen 
      presenting cells whose main role is diminished in a variety of malignancies, 
      including cancer, leading to ineffective immune responses. Those mechanisms are 
      inhibited due to the immunosuppressive conditions found in the tumor 
      microenvironment (TME), where myeloid-derived suppressor cells (MDSCs), a 
      heterogeneous population of immature myeloid cells known to play a key role in 
      tumor immunoevasion by inhibiting T-cell responses, are extremely accumulated. In 
      addition, it has been demonstrated that MDSCs not only suppress DC functions, but 
      also their maturation and development within the myeloid linage. Considering that 
      an increased number of DCs as well as the improvement in their functions boost 
      antitumor immunity, DC-based vaccines were developed two decades ago, and 
      promising results have been obtained throughout these years. Therefore, the 
      remodeling of the TME promoted by DC vaccination has also been explored. Here, we 
      aim to review the effectiveness of different DCs-based vaccines in murine models 
      and cancer patients, either alone or synergistically combined with other 
      treatments, being especially focused on their effect on the MDSC population.
CI  - Copyright (c) 2022 Sanchez-Leon, Jimenez-Cortegana, Cabrera, Vermeulen, de la 
      Cruz-Merino and Sanchez-Margalet.
FAU - Sanchez-Leon, Maria Luisa
AU  - Sanchez-Leon ML
AD  - Department of Medical Biochemistry and Molecular Biology, School of Medicine, 
      University of Seville, Seville, Spain.
AD  - Medical Oncology Service, Virgen Macarena University Hospital, Seville, Spain.
FAU - Jimenez-Cortegana, Carlos
AU  - Jimenez-Cortegana C
AD  - Department of Medical Biochemistry and Molecular Biology, School of Medicine, 
      University of Seville, Seville, Spain.
AD  - Department of Laboratory Medicine, Virgen Macarena University Hospital, Seville, 
      Spain.
FAU - Cabrera, Gabriel
AU  - Cabrera G
AD  - Laboratorio de Tecnologia Inmunologica, Facultad de Bioquimica y Ciencias 
      Biologicas, Universidad Nacional del Litoral, Santa Fe capital, Argentina.
FAU - Vermeulen, Elba Monica
AU  - Vermeulen EM
AD  - Laboratorio de Celulas Presentadoras de Antigeno y Respuesta Inflamatoria, 
      Instituto de Medicina Experimental (IMEX) - CONICET, Academia Nacional de 
      Medicina, Buenos Aires, Argentina.
FAU - de la Cruz-Merino, Luis
AU  - de la Cruz-Merino L
AD  - Medical Oncology Service, Virgen Macarena University Hospital, Seville, Spain.
FAU - Sanchez-Margalet, Victor
AU  - Sanchez-Margalet V
AD  - Department of Medical Biochemistry and Molecular Biology, School of Medicine, 
      University of Seville, Seville, Spain.
AD  - Department of Laboratory Medicine, Virgen Macarena University Hospital, Seville, 
      Spain.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20221115
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
SB  - IM
MH  - Humans
MH  - Animals
MH  - Mice
MH  - *Myeloid-Derived Suppressor Cells
MH  - Tumor Microenvironment
MH  - *Neoplasms/therapy
MH  - Myeloid Cells
MH  - Dendritic Cells
PMC - PMC9706090
OTO - NOTNLM
OT  - cancer
OT  - dendritic cells
OT  - immunosuppression
OT  - myeloid-derived suppressor cells
OT  - vaccines
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/12/03 06:00
MHDA- 2022/12/06 06:00
PMCR- 2022/01/01
CRDT- 2022/12/02 02:33
PHST- 2022/09/22 00:00 [received]
PHST- 2022/10/27 00:00 [accepted]
PHST- 2022/12/02 02:33 [entrez]
PHST- 2022/12/03 06:00 [pubmed]
PHST- 2022/12/06 06:00 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2022.1050484 [doi]
PST - epublish
SO  - Front Immunol. 2022 Nov 15;13:1050484. doi: 10.3389/fimmu.2022.1050484. 
      eCollection 2022.